The European clinical diagnostics businesses, Labco and synlab, today announce that Dr.
Bartl Wimmer will be appointed as Group Chief Executive and Philippe Charrier as
Executive Chairman of the combined group. This announcement follows the acquisitions of
Labco and synlab by European private equity firm Cinven in May and June respectively.
These positions will be effective once Cinven’s acquisitions of both Labco and synlab have
completed, which is expected to be in September 2015.
Dr. Bartl Wimmer is currently Chief Executive Officer of synlab. He was the co-founder of
the synlab business in 1998 and has acted as Managing Director since its establishment.
Since January 2010, he has held the position of CEO with responsibility for the successful
acquisition and integration of numerous medical diagnostics laboratories across Germany
Philippe Charrier is currently Chief Executive Officer of Labco. He joined the Board of
Labco in 2011 and was previously CEO of Oenobiol, the personal beauty care product
firm. During 1999 to 2006, he was CEO of P&G France. During his tenure as CEO,
Philippe Charrier has overseen significant growth and expansion at Labco the pre-eminent operator of clinical laboratories in Western Europe.
Dr Bartl Wimmer commented:
“I am delighted to be appointed Group CEO of the combined Labco/synlab business.
Both these companies are highly successful operators of medical diagnostics laboratories
across Europe and have grown strongly in recent years.
The combination of these businesses will enable us to continue developing first class
medical diagnostics and allow us to benefit from genuine benefits of scale where we can
provide diagnostic services more efficiently to patients and payors. Labco has an excellent
team and reputation and I am looking forward to working closely with Philippe Charrier as
Philippe Charrier added:
“The European clinical diagnostics sector is continuing to grow and the combined
Labco/synlab Group is extremely well positioned to benefit from the increasing demand for
clinical diagnostics services, particularly given the under penetrated and highly fragmented
European market. The combined Group will have the strongest medical capabilities in
Europe, and will be able to deliver new tests to market to provide improved patient
synlab is a highly respected operator within the market and, as Executive Chairman, it will
be my role to oversee the gradual combination of the two businesses in a way that
harnesses the best of both operations. I am looking forward to working with Bartl Wimmer
as Group CEO and believe that together the combined group has an exciting future
The completion of the Labco and synlab acquisitions remain subject to the satisfaction of
customary regulatory approval. These appointments are subject to the completion of the contemplated change of control and the forthcoming integration of these businesses.